Related references
Note: Only part of the references are listed.Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
P. Malfertheiner et al.
GUT (2017)
New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice
Antonio Tursi et al.
HELICOBACTER (2017)
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
William D. Chey et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
Jyh-Ming Liou et al.
GUT (2016)
Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection
P. -Y. Chen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area
Sotirios D. Georgopoulos et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2016)
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Carlo A. Fallone et al.
GASTROENTEROLOGY (2016)
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou et al.
LANCET (2016)
Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015
Rocco Maurizio Zagari et al.
DIGESTIVE AND LIVER DISEASE (2015)
Epidemiology of Helicobacter pylori Infection
Leonardo H. Eusebi et al.
HELICOBACTER (2014)
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication)
Alicia C. Marin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
Francis Megraud et al.
GUT (2013)
Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials
Hui-Lin Tang et al.
PLOS ONE (2013)
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?
C. A. M. McNulty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy
Francis Megraud
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2012)
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial
Peter Malfertheiner et al.
LANCET (2011)
The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy
PG Farup et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2002)
Current concepts in the management of Helicobacter pylori infection -: The Maastricht 2-2000 Consensus Report
P Malfertheiner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Current role of acid suppressants in Helicobacter pylori eradication therapy
J Labenz
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2001)
Share Paper
